My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

232.36 +0.07 (+0.03%)

Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

89 90 Next >

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential ↗

September 27, 2024

Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer option. Analysts project peak sales of up to $5 billion if approved for...

Via Benzinga

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years ↗

September 26, 2024

Via Benzinga

AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease ↗

September 26, 2024

AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug showed significant improvements in patient symptoms, meeting primary and...

Via Benzinga

Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead ↗

September 26, 2024

Even the mighty Novo Nordisk can't hold a candle to its peer in this area.

Via The Motley Fool

Behind the Scenes of AbbVie's Latest Options Trends ↗

September 24, 2024

Via Benzinga

Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years ↗

September 20, 2024

KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access challenges within the US healthcare system could limit its impact on mental...

Via Benzinga

Spotlight on AbbVie: Analyzing the Surge in Options Activity ↗

September 20, 2024

Via Benzinga

Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry ↗

September 19, 2024

Via Benzinga

Is ABBVIE INC Ready to Break Out of Its Range? ↗

September 17, 2024

Interesting Technical Analysis finding for ABBVIE INC (NYSE:ABBV)

Via Chartmill

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Via Investor's Business Daily

2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again ↗

September 19, 2024

For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again.

Via The Motley Fool

Topics Stocks

Abbie Inc Stocks Elliott Wave Technical Analysis - Wednesday, September 18, ↗

September 18, 2024

Looking for upside into wave {v} as we are trading within the parallel channel where we could eventually seek for support within wave {iv}.

Via Talk Markets

TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades' ↗

September 17, 2024

TransDigm Group (TDG), BJ's Wholesale (BJ), VanEck Semiconductor ETF (SMH), and AbbVie (ABBV) were recommended as top trades on CNBC's Halftime Report.

Via Benzinga

Topics ETFs

Can AbbVie Regain Its Status As a Top Dividend Growth Stock? ↗

September 16, 2024

The dividend growth powerhouse is turning the corner.

Via The Motley Fool

What the Options Market Tells Us About AbbVie ↗

September 11, 2024

Via Benzinga

Spotlight on AbbVie: Analyzing the Surge in Options Activity ↗

September 09, 2024

Via Benzinga

Peering Into AbbVie's Recent Short Interest ↗

September 06, 2024

Via Benzinga

Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today ↗

September 05, 2024

Via Benzinga

Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More ↗

September 14, 2024

Financial factors aren't the only things that are worth paying attention to.

Via The Motley Fool

3 Stocks to Buy and Hold Forever ↗

September 14, 2024

These stocks are built for the long run.

Via The Motley Fool

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗

September 14, 2024

Their dividends are solid. And their businesses are built for the long run.

Via The Motley Fool

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Via Talk Markets

Topics ETFs

Is This Company Still a Strong Buy After Tripling the S&P 500's Returns? ↗

September 13, 2024

The stock has been a winner, but there may be better times ahead for buying.

Via The Motley Fool

Topics Stocks

UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars ↗

September 11, 2024

UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs.

Via Benzinga

Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies ↗

September 10, 2024

Baltimore secures an $80 million settlement with Teva Pharmaceuticals in its opioid crisis litigation. Funds will be allocated to education, recovery centers, and outreach initiatives.

Via Benzinga

3 Things You Need to Know if You Buy AbbVie Stock Today ↗

September 09, 2024

This dynamic big pharma is undergoing a few key changes.

Via The Motley Fool

3 No-Brainer Dividend Stocks to Buy in September ↗

September 08, 2024

These stocks pay great dividends and could be long-term winners.

Via The Motley Fool

Earn $1,000 Per Month in Dividends From These 4 Stocks ↗

September 07, 2024

A mix of various types of dividend investments.

Via The Motley Fool

Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration ↗

September 05, 2024

The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.

Via Benzinga

Topics Artificial Intelligence

Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever ↗

September 05, 2024

There is something for everybody in America's $4.5 trillion healthcare market.

Via The Motley Fool

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

89 90 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition